Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 14:13:839380.
doi: 10.3389/fimmu.2022.839380. eCollection 2022.

Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review

Lara Cabezas  1 , Thomas Jouve  1   2 , Paolo Malvezzi  1 , Benedicte Janbon  1 , Diane Giovannini  2   3 , Lionel Rostaing  1   2 , Johan Noble  1   2
Affiliations

Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review

Lara Cabezas et al. Front Immunol. .

Abstract

Introduction: Chronic kidney disease (CKD) is a major public-health problem that increases the risk of end-stage kidney disease (ESKD), cardiovascular diseases, and other complications. Kidney transplantation is a renal-replacement therapy that offers better survival compared to dialysis. Antibody-mediated rejection (ABMR) is a significant complication following kidney transplantation: it contributes to both short- and long-term injury. The standard-of-care (SOC) therapy combines plasmapheresis and Intravenous Immunoglobulins (IVIg) with or without steroids, with or without rituximab: however, despite this combined treatment, ABMR remains the main cause of graft loss. IL-6 is a key cytokine: it regulates inflammation, and the development, maturation, and activation of T cells, B cells, and plasma cells. Tocilizumab (TCZ) is the main humanized monoclonal aimed at IL-6R and appears to be a safe and possible strategy to manage ABMR in sensitized recipients. We conducted a literature review to assess the place of the anti-IL-6R monoclonal antibody TCZ within ABMR protocols.

Materials and methods: We systematically reviewed the PubMed literature and reviewed six studies that included 117 patients and collected data on the utilization of TCZ to treat ABMR.

Results: Most studies report a significant reduction in levels of Donor Specific Antibodies (DSAs) and reduced inflammation and microvascular lesions (as found in biopsies). Stabilization of the renal function was observed. Adverse events were light to moderate, and mortality was not linked with TCZ treatment. The main side effect noted was infection, but infections did not occur more frequently in patients receiving TCZ as compared to those receiving SOC therapy.

Conclusion: TCZ may be an alternative to SOC for ABMR kidney-transplant patients, either as a first-line treatment or after failure of SOC. Further randomized and controlled studies are needed to support these results.

Keywords: antibody-mediated rejection; chronic active antibody-mediated rejection; donor-specific alloantibody; estimated glomerular filtration rate; kidney transplantation; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
IL-6 receptor targets of Tocilizumab in the development if antibody-mediated rejection.
See this image and copyright information in PMC

References

    1. Lv J-C, Zhang L-X. Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol (2019) 1165:3−15. doi: 10.1007/978-981-13-8871-2_1 - DOI - PubMed
    1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. . Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PloS One (2016) 11:e0158765. doi: 10.1371/journal.pone.0158765 - DOI - PMC - PubMed
    1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. . Worldwide Access to Treatment for End-Stage Kidney Disease: A Systematic Review. Lancet (2015) 385:1975−82. doi: 10.1016/S0140-6736(14)61601-9 - DOI - PubMed
    1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. . Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant. N Engl J Med (1999) 341:1725−30. doi: 10.1056/NEJM199912023412303 - DOI - PubMed
    1. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, et al. . A Study of the Quality of Life and Cost-Utility of Renal Transplantation. Kidney Int (1996) 50:235−42. doi: 10.1038/ki.1996.307 - DOI - PubMed

Publication types